Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 17/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777205 | 1.00 | EPHX1 (1.00) | EPHX1SMN1; SMN2MEN1FAAHMAPK1 | |
| SCHEMBL9784658 | 1.00 | EPHX1 (1.00) | EPHX1SMN1; SMN2MEN1FAAHMAPK1 | |
| SCHEMBL27052608 | 1.00 | EPHX1 (1.00) | EPHX1SMN1; SMN2MEN1FAAHMAPK1 | |
| SCHEMBL12196042 | 1.00 | EPHX1 (1.00) | EPHX1SMN1; SMN2MEN1FAAHMAPK1 | |
| SCHEMBL1896879 | 0.98 | EPHX1 (0.96) | EPHX1SMN1; SMN2MEN1FAAHMAPK1 | |
| SCHEMBL8394872 | 0.92 | EPHX1 (0.85) | EPHX1SMN1; SMN2MEN1FAAHMAPK1 | |
| SCHEMBL20953587 | 0.89 | EPHX1 (0.80) | EPHX1SMN1; SMN2MEN1MAPK1KMT2A | |
| SCHEMBL10808317 | 0.86 | EPHX1 (0.76) | EPHX1SMN1; SMN2 | |
| SCHEMBL8342142 | 0.86 | EPHX1 (0.76) | EPHX1SMN1; SMN2 | |
| SCHEMBL11780964 | 0.85 | EPHX1 (0.73) | EPHX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | EPHX1 3890/4885SMN1; SMN2 155/4885MEN1 4753/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | EPHX1 4523/4885SMN1; SMN2 52/4885MEN1 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.